080210xf's Blog

L'X fragile sera vaincu | Fragile X will be conquered

Santhera, Ipsen Sign $181M Collaboration for Fipamezole

By Cormac Sheridan,  BioWorld International Correspondent |

… Others pursuing that indication include Addex Pharmaceuticals SA, of Geneva, which is moving ADX48621, a negative allosteric modulator of metabotropic glutamate receptor 5, into a Phase II trial later this year. Basel, Switzerland-based Novartis AG began a Phase IIb trial of AFQ056, which acts on the same target, late last year. It said earlier this year that it planned to file for approval in 2012.


No comments yet»

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: